Attenuation of Compensation of Endogenous Cardiac Natriuretic Peptide System in Chronic Heart Failure

Ovid Technologies (Wolters Kluwer Health) - Tập 96 Số 2 - Trang 509-516 - 1997
Takayoshi Tsutamoto1, Atsuyuki Wada1, Keiko Maeda1, Tomoko Hisanaga1, Yusaku Maeda1, Daisuke Fukai1, Masato Ohnishi1, Yukihiko Sugimoto1, Masahiko Kinoshita1
1From the First Department of Internal Medicine, Shiga University of Medical Science, Tsukinowa, Seta, Otsu 520-21, Japan.

Tóm tắt

Background Patients with congestive heart failure (CHF) have high plasma levels of atrial natriuretic peptide (ANP), mainly from the atrium, and brain natriuretic peptide (BNP), mainly from the ventricle. We examined the prognostic role of plasma BNP in chronic CHF patients in comparison with plasma ANP and other variables previously known to be associated with high mortality. We also evaluated the relationship between mortality and plasma cGMP, a biological marker of ANP and BNP. Methods and Results The study subjects were 85 patients with chronic CHF (left ventricular ejection fraction <0.45) who were followed for 2 years. The plasma levels of ANP, BNP, cGMP, and norepinephrine increased with the severity of CHF. Among plasma levels of ANP, BNP, cGMP, and norepinephrine and clinical and hemodynamic parameters, only high levels of plasma BNP ( P <.0001) and pulmonary capillary wedge pressure ( P =.003) were significant independent predictors of the mortality in patients with CHF by Cox proportional hazard analysis. Although plasma levels of ANP and BNP were threefold or fivefold higher in nonsurvivors than in survivors, there was no difference in plasma cGMP level between nonsurvivors and survivors. Conclusions These findings indicate that plasma BNP is more useful than ANP for assessing the mortality in patients with chronic CHF and that the plasma levels of BNP provide prognostic information independent of other variables previously associated with a poor prognosis. Our findings also suggest that the compensatory activity of the cardiac natriuretic peptide system is attenuated as mortality increases in chronic CHF patients with high plasma levels of ANP and BNP.

Từ khóa


Tài liệu tham khảo

10.7326/0003-4819-101-3-370

10.1056/NEJM198409273111303

Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 1988:77;721-729.

10.1136/hrt.65.5.249

10.7326/0003-4819-114-6-464

Cody RJ, Hass GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with extent of pulmonary hypertension in patients with chronic heart failure. Circulation. 1994;85:504-509.

10.1016/0735-1097(94)90387-5

10.1161/circ.82.5.2225374

10.1016/0735-1097(94)90001-9

10.1016/S0002-9149(99)80231-8

10.1016/0735-1097(89)90344-6

10.1161/circ.89.5.8181115

10.1016/S0002-9149(99)80748-6

10.1161/circ.87.2.8425293

10.1161/circ.88.1.8319360

10.1016/0140-6736(93)93126-L

10.1161/circ.90.1.8025996

10.1161/circ.73.6.2938846

10.1016/S0735-1097(86)80086-9

10.1056/NEJM198608283150901

Tsutamoto T Bito K Kinoshita M. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J. 1989:117;599-606.

10.1016/0735-1097(92)90005-8

10.1161/circ.87.1.8093432

10.1038/338078a0

10.1210/jcem-61-6-1217

10.1073/pnas.83.20.8015

Cusson JR, Hamet P, Gutkowaka J, Kuchel O, Genest J, Cantin M, Larochelle P. Effects of atrial natriuretic factor on natriuresis and cGMP in patients with essential hypertension. J Hypertens. 1987;117:599-606.

Heim JM Gottmann K Weil J Haufe MC Gerzer R. Is cyclic GMP a clinical useful marker for ANF action? Z Kardiol. 1988;77(suppl 2):41-46.

10.1161/circ.90.2.8044954

10.1161/circ.89.5.7910118

10.1016/0014-2999(89)90273-2

10.1038/332078a0

10.1172/JCI115146

10.1161/circ.84.4.1914098

10.1016/0006-291X(89)92268-7

Nakao K, Mukoyama M, Hosoda K, Suga S, Ogawa Y, Saito Y, Shirakami G, Arai H, Jougasaki M, Imura H. Biosynthesis, secretion, and receptor selectivity of human brain natriuretic peptide. Can J Physiol Pharmacol. 1991;87:1402-1412.

10.1161/circ.92.6.1558

10.1016/S0002-9149(99)80071-X

10.1161/circ.93.11.1963

Thông tin
Thông tin xuất bản

Ovid Technologies (Wolters Kluwer Health)

Tập 96 Số 2

509-516

Thông tin tác giả